专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2638055A4 CONSENSUS PROSTATE ANTIGENS NUCLEIC ACID MOLECULE ENCODING THE SAME AND VACCINE AND USES COMPRISING THE SAME 有权转让
标题翻译：前列腺共有抗原，核酸编码分子和疫苗及其用途与
公开(公告)号：EP2638055A4
公开(公告)日：2015-12-30
申请号：EP11839215
申请日：2011-11-14
申请人： UNIV PENNSYLVANIA , INOVIO PHARMACEUTICALS INC
发明人： WEINER DAVID B , YAN JIAN , FERRARO BERNADETTE , SARDESAI NIRANJAN Y , RAMANATHAN MATHURA P
IPC分类号： C07H21/00 , C07K14/00
CPC分类号： A61K39/0011 , A61K39/00 , A61K2039/53 , C07K14/4748 , C12N9/485 , C12N9/6424 , C12Y116/01 , C12Y304/17021 , C12Y304/21077
摘要： Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.

2. 发明公开

EP2621540A4 CONSENSUS ANTIGEN CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME TO TREAT MALARIA 无效转让
标题翻译：共识抗原构建和疫苗由其制造及其使用FOR疟疾的治疗方法
公开(公告)号：EP2621540A4
公开(公告)日：2014-08-27
申请号：EP11831320
申请日：2011-09-27
申请人： UNIV PENNSYLVANIA , INOVIO PHARMACEUTICALS INC
发明人： WEINER DAVID B , SARDESAI NIRANJAN Y
IPC分类号： A61K48/00
CPC分类号： A61K39/015 , A61K38/195 , A61K38/20 , A61K38/208 , A61K38/2086 , A61K2039/53 , A61K2039/54 , A61K2039/55527 , A61K2039/70 , C07K14/445
摘要： Provided herein is consensus amino acid sequences of P. falciparum (P.f.) proteins and their encoding sequences, as well as expression constructs expressing the sequences. Also provided herein are methods for generating an immune response against P. falciparum using the expression constructs provided herein.
摘要翻译：在提供的是恶性疟原虫（P. F.）蛋白及其编码序列的共有氨基酸序列，以及表达构建表达该序列。因此，对于使用所提供的表达构建体在抗恶性疟原虫的免疫应答产生在提供了一些方法。

3. 发明公开

EP2741785A4 NOVEL CLOSTRIDIUM DIFFICILE DNA VACCINE 失效转让
标题翻译：中性离子 - 差异DNA-IMPFSTOFF
公开(公告)号：EP2741785A4
公开(公告)日：2015-03-25
申请号：EP12840108
申请日：2012-07-12
申请人： PHILADELPHIA HEALTH & EDUCATIO , INOVIO PHARMACEUTICALS INC , UNIV PENNSYLVANIA
发明人： KUTZLER MICHELE , BALIBAN SCOTT , WEINER DAVID B , SARDESAI NIRANJAN Y , KIM J JOSEPH
IPC分类号： A61K48/00 , A61K39/08 , C12N15/17 , C12N15/31 , C12N15/85
CPC分类号： A61K39/08 , A61K2039/53 , A61N1/327 , C07K14/33
摘要： The invention relates to compositions and methods for treating C. difficile associated disease (CDAD) through the administration to a subject in need thereof at least one nucleic acid encoding at least a portion of at least one of toxin A and toxin B.
摘要翻译：本发明涉及通过向有需要的受试者施用编码毒素A和毒素B中的至少一种的至少一部分的至少一种核酸来治疗艰难梭菌相关疾病（CDAD）的组合物和方法。

4. 发明公开

EP3226892A4 DNA ANTIBODY CONSTRUCTS AND METHOD OF USING SAME 审中-实审
公开(公告)号：EP3226892A4
公开(公告)日：2018-07-18
申请号：EP15864627
申请日：2015-12-01
申请人： UNIV PENNSYLVANIA , INOVIO PHARMACEUTICALS INC
发明人： WEINER DAVID B , MUTHUMANI KARUPPIAH , FLINGAI SELEEKE , SARDESAI NIRANJAN
IPC分类号： A61K39/00 , A61K39/395
CPC分类号： A61K39/39558 , A61K48/0016 , A61K48/0066 , A61K2039/505 , A61K2039/53 , C07K14/82 , C07K16/00 , C07K16/1063 , C07K16/1081 , C07K16/28 , C07K16/3069 , C07K16/32 , C07K2317/21 , C07K2317/55 , C07K2317/76 , C07K2319/00 , C07K2319/02 , C12N15/09 , C12N2800/107 , C12N2800/22 , C12N2830/50 , C12N2840/60 , G01N33/531
摘要： Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.

5. 发明公开

EP3080159A4 DNA ANTIBODY CONSTRUCTS AND METHOD OF USING SAME 审中-实审
标题翻译： DNA-ANTIKÖRPERKONSTRUKTEUND VERFAHREN ZUR VERWENDUNG DAVON
公开(公告)号：EP3080159A4
公开(公告)日：2017-08-02
申请号：EP14869248
申请日：2014-12-13
申请人： UNIV PENNSYLVANIA , INOVIO PHARMACEUTICALS INC
发明人： WEINER DAVID B , MUTHUMANI KARUPPIAH , FLINGAI SELEEKE , SARDESAI NIRANJAN
IPC分类号： C07K16/10 , A61K39/12 , A61K39/42
CPC分类号： C07K16/1081 , A61K48/005 , A61K2039/505 , A61K2039/53 , A61K2039/54 , A61M37/00 , A61M2037/0007 , A61N1/327 , C07K16/10 , C07K16/1063 , C07K16/32 , C07K2317/10 , C07K2317/51 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/60 , C07K2317/76 , C07K2319/00 , C12N7/00 , C12N2740/16032 , C12N2740/16111 , C12N2740/16122 , C12N2770/24111 , C12N2770/24122 , C12N2770/24133 , C12N2770/24171 , C12N2770/36111 , C12N2770/36122 , C12N2770/36133 , C12N2770/36171
摘要： Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
摘要翻译：本文公开了包含编码抗体的重组核酸序列的组合物。本文还公开了通过将组合物施用于受试者而在受试者中产生合成抗体的方法。本公开还提供了使用所述组合物和产生方法预防和/或治疗受试者中的疾病的方法。

6. 发明公开

EP2931304A4 WT1 VACCINE 有权转让
标题翻译： WT1-IMPFSTOFF
公开(公告)号：EP2931304A4
公开(公告)日：2016-07-20
申请号：EP13861986
申请日：2013-12-13
申请人： UNIV PENNSYLVANIA , INOVIO PHARMACEUTICALS INC
发明人： WEINER DAVID B , YAN JIAN , WALTERS JEWELL
IPC分类号： A61K39/00 , A61K39/38 , C07K14/47 , C12N15/64 , C12P19/34
CPC分类号： A61K39/0011 , A61K2039/53 , C07K14/4748
摘要： Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated WT1 antigen. Vectors, compositions and vaccines comprising one or more nucleic acid sequences that encode a mutated WT1 antigen are disclosed. Methods of treating an individual who has a WT1-expressing tumor and methods of preventing a WT1-expressing tumor are disclosed. Mutated WT1 antigen is disclosed.
摘要翻译：本文公开了包含编码突变的WT1抗原的一个或多个核酸序列的核酸分子。公开了包含编码突变的WT1抗原的一个或多个核酸序列的载体，组合物和疫苗。公开了治疗具有WT1表达肿瘤的个体的方法和预防表达WT1的肿瘤的方法。公开了突变的WT1抗原。

7. 发明公开

EP2968519A4 FOOT AND MOUTH DISEASE VIRUS (FMDV) CONSENSUS PROTEINS, CODING SEQUENCES THEREFOR AND VACCINES MADE THEREFROM 有权
标题翻译：用于手足口病病毒编码序列的共有蛋白体和疫苗由其MADE
公开(公告)号：EP2968519A4
公开(公告)日：2016-03-30
申请号：EP14765406
申请日：2014-03-17
申请人： UNIV PENNSYLVANIA , INOVIO PHARMACEUTICALS INC
发明人： WEINER DAVID B , MUTHUMANI KARUPPIAH , YAN JIAN , SARDESAI NIRANJAN Y
IPC分类号： A61K39/12 , A61K39/00 , A61K39/125 , A61K39/135
CPC分类号： A61K39/135 , A61K39/12 , A61K2039/53 , A61K2039/552 , C07K14/005 , C12N7/00 , C12N2770/32134
摘要： The present invention relates to synthetic, consensus foot-and-mouth disease virus (FMDV) immunogenic proteins and nucleic acid molecule encoding such proteins, to vaccines against FMDV, to methods for inducing immune responses against FMVD, to methods for distinguishing between individuals infected with FMDV versus those vaccinated against FMDV, and methods of prophylactically and/or therapeutically immunizing individuals against FMDV.

8. 发明公开

EP3200831A4 VACCINES HAVING AN ANTIGEN AND INTERLEUKIN-21 AS AN ADJUVANT 审中-实审
公开(公告)号：EP3200831A4
公开(公告)日：2018-02-21
申请号：EP15845692
申请日：2015-09-29
申请人： UNIV PENNSYLVANIA , INOVIO PHARMACEUTICALS INC
发明人： WEINER DAVID B , MORROW MATTHEW P
IPC分类号： A61K48/00 , A61B17/20 , A61K39/00
CPC分类号： A61K39/39 , A61K39/08 , A61K39/12 , A61K39/21 , A61K41/0047 , A61K48/00 , A61K2039/53 , A61K2039/55527 , A61N1/327 , C07K14/54 , C12N2740/16134
摘要： Disclosed herein is a vaccine comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.

9. 发明公开

EP3068427A4 HIV-1 ENV DNA VACCINE PLUS PROTEIN BOOST 无效
标题翻译： HIV-1 ENV DNA VACCINE PLUS蛋白质增加
公开(公告)号：EP3068427A4
公开(公告)日：2016-09-21
申请号：EP14861787
申请日：2014-11-06
申请人： UNIV PENNSYLVANIA , INOVIO PHARMACEUTICALS INC
发明人： WEINER DAVID B , MUTHUMANI KARUPPIAH , WISE MEGAN , YAN JIAN , BRODERICK KATE
IPC分类号： A61K39/21 , C07K14/16 , C12P19/34
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/53 , A61K2039/545 , A61K2039/57 , A61K2039/575 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N2740/16122 , C12N2740/16134 , C12N2740/16171
摘要： The present invention is directed to an effective HIV vaccine will most likely require the induction of strong T-cell responses, broadly neutralizing antibodies (bNAbs), and the elicitation of antibody-dependent cellular cytotoxicity (ADCC). Previously, we demonstrated the induction of strong HIV/SIV cellular immune responses in macaques and humans using synthetic consensus DNA immunogens delivered via adaptive electroporation (EP). However, the ability of this improved DNA approach to prime for relevant antibody responses has not been previously studied. Here, we investigate the immunogenicity of consensus DNA constructs encoding gp140 sequences from HIV-1 subtypes A, B, C and D in a DNA prime protein boost vaccine regimen. Mice and Guinea pigs were primed with single and multi-clade DNA via EP and boosted with recombinant gp120 protein. Sera were analyzed for gp120 binding and induction of neutralizing antibody activity. Immunization with recombinant Env protein alone induced low-titer binding antibodies with limited neutralization breath. In contrast the synthetic DNA prime protein boost protocol was induced significantly higher antibody binding titers. Furthermore, sera from DNA prime-protein boost groups were able to neutralize a broader range of viruses in a panel of tier 1 clade B viruses as well as multiple tier 1 clade A and clade C viruses. Further investigation of synthetic DNA prime+adaptive EP plus protein boost appears warranted.
摘要翻译：本发明涉及有效的HIV疫苗很可能需要诱导强T细胞应答，广泛中和抗体（bNAb）以及诱导抗体依赖性细胞毒性（ADCC）。以前，我们通过使用通过自适应电穿孔（EP）递送的合成共识DNA免疫原，证明了在猕猴和人类中诱导强烈的HIV / SIV细胞免疫应答。然而，这种改进的DNA方法为相关抗体反应引发的能力以前没有被研究过。在这里，我们调查编码来自HIV-1亚型A，B，C和D的gp140序列的DNA初步蛋白增强疫苗方案的共有DNA构建体的免疫原性。小鼠和豚鼠用单次和多次进化枝DNA通过EP引发，并用重组gp120蛋白加强。分析血清中的gp120结合和中和抗体活性的诱导。用重组Env蛋白单独免疫诱导具有有限中和呼吸的低滴度结合抗体。相比之下，合成DNA初始蛋白增强方案诱导显着更高的抗体结合滴度。此外，来自DNA初始蛋白增强组的血清能够在1级进化枝B病毒以及多个1级进化枝A和进化枝C病毒的小组中中和更广泛的病毒。进一步研究合成DNA素+自适应EP加蛋白质增强似乎是有必要的。

10. 发明公开

EP3074051A4 MERS-COV VACCINE 审中-实审
标题翻译： MERS冠状病毒疫苗
公开(公告)号：EP3074051A4
公开(公告)日：2017-04-12
申请号：EP14866748
申请日：2014-11-26
申请人： UNIV PENNSYLVANIA , INOVIO PHARMACEUTICALS INC
发明人： WEINER DAVID B , MUTHUMANI KARUPPIAH , SARDESAI NIRANJAN Y
IPC分类号： A61K48/00 , A61K38/16 , A61K39/00 , A61K39/12 , A61K39/215
CPC分类号： A61K39/215 , A61K39/12 , A61K2039/53 , C12N7/00 , C12N2770/20034
摘要： Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式